research use only

PMA chemical (Phorbol 12-myristate 13-acetate) PKC activator

Name: PMA chemical (Phorbol 12-myristate 13-acetate)
Brand: Selleck Chemicals
SKU: S7791
Availability: InStock
Rating: 5 (79 reviews)

Cat.No.S7791

PMA (Phorbol 12-myristate 13-acetate), a potent activator of PKC, is active at nanomolar concentrations. Phorbol 12-myristate 13-acetate (PMA) induces sphingosine-1-phosphate (S1P).PMA has strong excitability on the skin and mucous membrane. Special protection is required when using PMA. Wear gloves and mask to avoid direct contact in any way.

Chemical Structure

Molecular Weight: 616.83

Jump to

Quality Control

Batch: Purity: 99.93%

99.93

Products Often Used Together with PMA chemical (Phorbol 12-myristate 13-acetate)

Tangeretin

Tangeretin significantly inhibits epidermal hyperplasia and intra-epidermal neutrophilic abscesses in mice stimulated by this compound.

Curcumin

Curcumin reduces the elevation of uric acid induced by this compound in NIH3T3 cells.

Forskolin (Colforsin)

Phorbol 12-myristate 13-acetate (PMA) and Forskolin are strongly synergistic in altering endothelial cell morphology.

Related Targets	Akt Wnt/beta-catenin HSP ROCK Microtubule Associated Integrin Bcr-Abl Actin FAK Kinesin
Other PKC Products	Go 6983 Enzastaurin Sotrastaurin (AEB071) Bisindolylmaleimide I (GF109203X) Go6976 Bisindolylmaleimide IX (Ro 31-8220) Mesylate Ruboxistaurin (LY333531) Hydrochloride Rottlerin PKC-theta inhibitor Chelerythrine Chloride (NSC 646662)

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (162.11 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (8.11mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (8.11mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	616.83	Formula	C₃₆H₅₆O₈	Storage (From the date of receipt)	3 years -20°C(in the dark) powder
CAS No.	16561-29-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	12-O-Tetradecanoylphorbol-13-acetate,TPA, Phorbol myristate acetate			Smiles	CCCCCCCCCCCCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)C)O)C

Mechanism of Action

In vitro	In endothelial cells, PMA (Phorbol 12-myristate 13-acetate) increases levels of Thy-1 mRNA and protein, induces Thy-1 up-regulation and inhibits capillary-like tube formation and endothelial cell migration.
In vivo	In the zebrafish model, PMA (Phorbol 12-myristate 13-acetate) initially enhances endothelial cell migration, subsequently activating the PKC-δ/Syk/NF-κB-mediated pathway to up-regulate Thy-1, which in turn inhibits endothelial cell migration.
References	[1] https://pubmed.ncbi.nlm.nih.gov/30389973/

Applications

Methods	Biomarkers	Images	PMID
Western blot	pERK / ERK1 / pp38 / p38 p-GSK3β / GSK3β / Lamin B2		22977714
Immunofluorescence	cTnT / β-MHC / CD90		27405982

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06327152	Recruiting	Apnea of Prematurity	University of California Irvine	February 22 2024	Phase 2
NCT05908227	Recruiting	Respiratory Distress Syndrome	Insel Gruppe AG University Hospital Bern	July 1 2023	Not Applicable
NCT06318585	Recruiting	Amyotrophic Lateral Sclerosis\|Motor Neuron Disease	Istituto Auxologico Italiano	April 3 2023	--
NCT06087666	Recruiting	Preterm	Instituto de Investigación Hospital Universitario La Paz	February 1 2023	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):